These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
329 related articles for article (PubMed ID: 16428784)
21. A subdose of fluconazole alters the virulence of Cryptococcus gattii during murine cryptococcosis and modulates type I interferon expression. Fontes AC; Bretas Oliveira D; Santos JR; Carneiro HC; Ribeiro NQ; Oliveira LV; Barcellos VA; Paixão TA; Abrahão JS; Resende-Stoianoff MA; Vainstein MH; Santos DA Med Mycol; 2017 Feb; 55(2):203-212. PubMed ID: 27486215 [TBL] [Abstract][Full Text] [Related]
22. Aneuploidy underlies brefeldin A-induced antifungal drug resistance in Zhang ZH; Sun LL; Fu BQ; Deng J; Jia CL; Miao MX; Yang F; Cao YB; Yan TH Front Cell Infect Microbiol; 2024; 14():1397724. PubMed ID: 38966251 [No Abstract] [Full Text] [Related]
23. A P4-ATPase subunit of the Cdc50 family plays a role in iron acquisition and virulence in Cryptococcus neoformans. Hu G; Caza M; Bakkeren E; Kretschmer M; Bairwa G; Reiner E; Kronstad J Cell Microbiol; 2017 Jun; 19(6):. PubMed ID: 28061020 [TBL] [Abstract][Full Text] [Related]
24. New Triazole NT-a9 Has Potent Antifungal Efficacy against Cryptococcus neoformans Lu RY; Ni TJ; Wu J; Yan L; Lv QZ; Li LP; Zhang DZ; Jiang YY Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31791946 [TBL] [Abstract][Full Text] [Related]
25. Lanoconazole, a new imidazole antimycotic compound, protects MAIDS mice against encephalitis caused by Cryptococcus neoformans. Furukawa K; Sasaki H; Pollard RB; Suzuki F J Antimicrob Chemother; 2000 Sep; 46(3):443-50. PubMed ID: 10980172 [TBL] [Abstract][Full Text] [Related]
26. Identification of a Cryptococcus neoformans cytochrome P450 lanosterol 14α-demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole. Sionov E; Chang YC; Garraffo HM; Dolan MA; Ghannoum MA; Kwon-Chung KJ Antimicrob Agents Chemother; 2012 Mar; 56(3):1162-9. PubMed ID: 22155829 [TBL] [Abstract][Full Text] [Related]
27. In-vitro and in-vivo activities of SCH56592 against Cryptococcus neoformans. Hossain MA; Maesaki S; Mitsutake K; Kakeya H; Sasaki E; Tomono K; Tashiro T; Kohno S J Antimicrob Chemother; 1999 Dec; 44(6):827-9. PubMed ID: 10590286 [TBL] [Abstract][Full Text] [Related]
29. Prophylactic role of liposomized chloroquine against murine cryptococcosis less susceptible to fluconazole. Khan MA; Jabeen R; Mohammad O Pharm Res; 2004 Dec; 21(12):2207-12. PubMed ID: 15648251 [TBL] [Abstract][Full Text] [Related]
30. Natural compounds from freshwater mussels disrupt fungal virulence determinants and influence fluconazole susceptibility in the presence of macrophages in Gutierrez-Gongora D; Woods M; Prosser RS; Geddes-McAlister J Microbiol Spectr; 2024 Mar; 12(3):e0284123. PubMed ID: 38329361 [TBL] [Abstract][Full Text] [Related]
31. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole. Chang WN; Huang CR; Lei CB; Lee PY; Chien CC; Chang HW; Chang CS; Lu CH Jpn J Infect Dis; 2004 Jun; 57(3):113-5. PubMed ID: 15218221 [TBL] [Abstract][Full Text] [Related]
32. A defect in iron uptake enhances the susceptibility of Cryptococcus neoformans to azole antifungal drugs. Kim J; Cho YJ; Do E; Choi J; Hu G; Cadieux B; Chun J; Lee Y; Kronstad JW; Jung WH Fungal Genet Biol; 2012 Nov; 49(11):955-66. PubMed ID: 22975303 [TBL] [Abstract][Full Text] [Related]
33. Astemizole and an analogue promote fungicidal activity of fluconazole against Cryptococcus neoformans var. grubii and Cryptococcus gattii. Vu K; Gelli A Med Mycol; 2010 Mar; 48(2):255-62. PubMed ID: 19572230 [TBL] [Abstract][Full Text] [Related]
34. Fatty acid synthesis is essential for survival of Cryptococcus neoformans and a potential fungicidal target. Chayakulkeeree M; Rude TH; Toffaletti DL; Perfect JR Antimicrob Agents Chemother; 2007 Oct; 51(10):3537-45. PubMed ID: 17698629 [TBL] [Abstract][Full Text] [Related]
35. Antiphagocytic protein 1 increases the susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole. Ghaffar M; Orr C; Webb G PLoS One; 2019; 14(12):e0225701. PubMed ID: 31800598 [TBL] [Abstract][Full Text] [Related]
37. Overexpression of TUF1 restores respiratory growth and fluconazole sensitivity to a Cryptococcus neoformans vad1Delta mutant. Panepinto JC; Misener AL; Oliver BG; Hu G; Park YD; Shin S; White TC; Williamson PR Microbiology (Reading); 2010 Aug; 156(Pt 8):2558-2565. PubMed ID: 20430817 [TBL] [Abstract][Full Text] [Related]
38. A Small Protein Associated with Fungal Energy Metabolism Affects the Virulence of Cryptococcus neoformans in Mammals. McClelland EE; Ramagopal UA; Rivera J; Cox J; Nakouzi A; Prabu MM; Almo SC; Casadevall A PLoS Pathog; 2016 Sep; 12(9):e1005849. PubMed ID: 27583447 [TBL] [Abstract][Full Text] [Related]
39. In vivo development of fluconazole resistance in serial Cryptococcus gattii isolates from a cat. Sykes JE; Hodge G; Singapuri A; Yang ML; Gelli A; Thompson GR Med Mycol; 2017 Jun; 55(4):396-401. PubMed ID: 28339594 [TBL] [Abstract][Full Text] [Related]
40. Activity of sertraline against Cryptococcus neoformans: in vitro and in vivo assays. Treviño-Rangel Rde J; Villanueva-Lozano H; Hernández-Rodríguez P; Martínez-Reséndez MF; García-Juárez J; Rodríguez-Rocha H; González GM Med Mycol; 2016 Mar; 54(3):280-6. PubMed ID: 26705833 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]